

**Report of the Directors and
Financial Statements
for the Year Ended 31 March 2026
for
TRUPCR Europe Limited**

TRUPCR Europe Limited

**Contents of the Financial Statements
for the Year Ended 31 March 2026**

	Page
Company Information	1
Report of the Directors	2
Report of the Independent Auditors	3
Statement of Comprehensive Income	7
Balance Sheet	8
Notes to the Financial Statements	10
Trading and Profit and Loss Account	16

TRUPCR Europe Limited
Company Information
for the Year Ended 31 March 2026

DIRECTORS:

H Singh
N K Dubey
D Dubey

REGISTERED OFFICE:

Unit 6, Williams House
Lloyd Street North
Manchester Science Park
Manchester
M15 6SE

REGISTERED NUMBER:

12060630 (England and Wales)

SENIOR STATUTORY AUDITOR: Ian Sluckis BA FCA

AUDITORS:

Freedman Frankl & Taylor
Statutory Auditors
Chartered Accountants
Reedham House
31 King Street West
Manchester
M3 2PJ

TRUPCR Europe Limited
Report of the Directors
for the Year Ended 31 March 2026

The directors present their report with the financial statements of the company for the year ended 31 March 2026.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 April 2025 to the date of this report.

H Singh
N K Dubey
D Dubey

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Harinder Singh

.....
H Singh - Director

30 Jun 2026

Date:

Report of the Independent Auditors to the Members of TRUPCR Europe Limited

Opinion

We have audited the financial statements of TRUPCR Europe Limited (the 'company') for the year ended 31 March 2026 which comprise the Statement of Comprehensive Income, Balance Sheet and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2026 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

**Report of the Independent Auditors to the Members of
TRUPCR Europe Limited**

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Directors.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of TRUPCR Europe Limited

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- the nature of the industry and sector, control environment and business performance;
- results of enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the Company's documentation of their policies and procedures relating to:
 - identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
 - detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team and involving other internal specialists including tax regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risks of management override.

We also obtained an understanding of the legal and regulatory frameworks that the Company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and local tax legislation.

Our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
 - enquiring of management concerning actual and potential litigation and claims;
 - performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
 - obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and
 - in addressing the risks of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
- We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

**Report of the Independent Auditors to the Members of
TRUPCR Europe Limited**

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Ian Sluckis

Ian Sluckis BA FCA (Senior Statutory Auditor)
for and on behalf of Freedman Frankl & Taylor
Statutory Auditors
Chartered Accountants
Reedham House
31 King Street West
Manchester
M3 2PJ
30 Jun 2026

Date:

TRUPCR Europe Limited
Statement of Comprehensive
Income
for the Year Ended 31 March 2026

	2026 £	2025 £
TURNOVER	1,750,863	1,287,580
Cost of sales	(1,148,559)	(856,236)
GROSS PROFIT	602,304	431,344
Administrative expenses	(466,814)	(432,384)
	135,490	(1,040)
Other operating income	20,395	4,095
OPERATING PROFIT	155,885	3,055
Interest receivable and similar income	29	1,262
	155,914	4,317
Interest payable and similar expenses	(6,670)	(257)
PROFIT BEFORE TAXATION	149,244	4,060
Tax on profit	-	5,644
PROFIT FOR THE FINANCIAL YEAR	149,244	9,704
OTHER COMPREHENSIVE INCOME	-	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	149,244	9,704

The notes form part of these financial statements

TRUPCR Europe Limited (Registered number: 12060630)

**Balance Sheet
31 March 2026**

	Notes	2026 £	2025 £
FIXED ASSETS			
Intangible assets	3	-	2,796
Tangible assets	4	68,590	73,785
Investments	5	829,500	-
		<u>898,090</u>	<u>76,581</u>
CURRENT ASSETS			
Stocks	6	47,039	54,473
Debtors	7	562,991	271,825
Cash at bank		393,565	559,747
		<u>1,003,595</u>	<u>886,045</u>
CREDITORS			
Amounts falling due within one year	8	(712,549)	(184,234)
NET CURRENT ASSETS		<u>291,046</u>	<u>701,811</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		1,189,136	778,392
CREDITORS			
Amounts falling due after more than one year	9	(262,500)	(1,000)
NET ASSETS		<u>926,636</u>	<u>777,392</u>
CAPITAL AND RESERVES			
Called up share capital	11	1,000	1,000
Share premium		869,400	869,400
Retained earnings		56,236	(93,008)
SHAREHOLDERS' FUNDS		<u>926,636</u>	<u>777,392</u>

The notes form part of these financial statements

TRUPCR Europe Limited (Registered number: 12060630)

**Balance Sheet - continued
31 March 2026**

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

30 Jun 2026

The financial statements were approved by the Board of Directors and authorised for issue on
and were signed on its behalf by:

Harinder Singh

.....
H Singh - Director

Nikhil Dubey

.....
N K Dubey - Director

The notes form part of these financial statements

TRUPCR Europe Limited

Notes to the Financial Statements for the Year Ended 31 March 2026

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates

In applying the company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Key sources of estimation uncertainty

The key assumptions concerning the future, and other key sources of estimation uncertainty, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are disclosed below.

Assessing indicators of impairment

In assessing whether there have been any indicators of impairment assets, the directors have considered both external and internal sources of information such as market conditions and experience of recoverability. There have been no indicators of impairments identified during the current financial year.

Tangible fixed assets

Tangible fixed assets, are depreciated over their useful lives taking into account residual values, where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projected disposal values.

Turnover

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates and value added tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Interest Income

Interest income is recognised on an accrual basis, when the entity obtains the right to receive the income.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

TRUPCR Europe Limited

Notes to the Financial Statements - continued for the Year Ended 31 March 2026

Development costs are being amortised evenly over their estimated useful life of three years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Improvements to property	- The period of the lease
Plant and machinery	- Straight line over 15 years
Fixtures and fittings	- Straight line over 10 years
Computer equipment	- Straight line over 3 years

Tangible fixed assets are recorded at cost less any tax, discounts and rebates. Subsequently they are recorded at cost less accumulated depreciation and impairment.

Government grants

Grants of a revenue nature are credited to income in the period to which they relate.

Investments in associates

Investments in associate undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

TRUPCR Europe Limited

**Notes to the Financial Statements - continued
for the Year Ended 31 March 2026**

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern

The company's financial statements for the year ended 31 March 2026 have been prepared on a going concern basis as, after making appropriate enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

Contingent liabilities

Deferred consideration is recognised at the fair value of the amount expected to be paid. Where the settlement is deferred beyond normal credit terms, the liability is measured at the present value of the future payments, discounted at a market rate of interest for a similar debt instrument. The unwinding of the discount is recognised as a finance cost in the Profit and Loss account over the period of deferral.

2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2025 - 6).

3. INTANGIBLE FIXED ASSETS

	Development costs £
COST	
At 1 April 2025	
and 31 March 2026	8,389
AMORTISATION	
At 1 April 2025	5,593
Amortisation for year	2,796
At 31 March 2026	8,389
NET BOOK VALUE	
At 31 March 2026	-
At 31 March 2025	2,796

TRUPCR Europe Limited

**Notes to the Financial Statements - continued
for the Year Ended 31 March 2026**

4. TANGIBLE FIXED ASSETS

	Improvements to property £	Plant and machinery £	Fixtures and fittings £	Computer equipment £	Totals £
COST					
At 1 April 2025	35,915	72,965	6,597	3,981	119,458
Additions	110	1,441	902	1,810	4,263
At 31 March 2026	36,025	74,406	7,499	5,791	123,721
DEPRECIATION					
At 1 April 2025	28,437	12,944	1,886	2,406	45,673
Charge for year	2,530	4,897	683	1,348	9,458
At 31 March 2026	30,967	17,841	2,569	3,754	55,131
NET BOOK VALUE					
At 31 March 2026	5,058	56,565	4,930	2,037	68,590
At 31 March 2025	7,478	60,021	4,711	1,575	73,785

5. FIXED ASSET INVESTMENTS

	Interest in associate £
COST	
Additions	829,500
At 31 March 2026	829,500
NET BOOK VALUE	
At 31 March 2026	829,500

The company investments at the balance sheet date in the share capital of unlisted companies include the following:

Coris Holdings SRL

Registered office: Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium

Nature of business: Activities of holding companies

	% holding
Class of shares:	
Ordinary shares	30.00

6. STOCKS

	2026 £	2025 £
Good for resale	47,039	54,473

TRUPCR Europe Limited

**Notes to the Financial Statements - continued
for the Year Ended 31 March 2026**

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2026	2025
	£	£
Trade debtors	427,054	231,913
Other debtors	135,937	39,912
	<u>562,991</u>	<u>271,825</u>

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2026	2025
	£	£
Trade creditors	11,330	8,401
Amounts owed to group undertakings	493,233	161,904
Taxation and social security	5,022	-
Other creditors	202,964	13,929
	<u>712,549</u>	<u>184,234</u>

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2026	2025
	£	£
Amounts owed to group undertakings	262,500	-
Other creditors	-	1,000
	<u>262,500</u>	<u>1,000</u>

10. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2026	2025
	£	£
Within one year	39,248	16,849
Between one and five years	58,872	-
	<u>98,120</u>	<u>16,849</u>

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2026	2025
			£	£
1,000	Ordinary	£1	<u>1,000</u>	<u>1,000</u>

12. CONTINGENT LIABILITIES

Contingent consideration is payable in relation to the acquisition of the group undertaking. The amount recognised of £184,500 represents the directors' best estimate of the liability due under the terms of the purchase agreement, based on management's performance expectations.

TRUPCR Europe Limited

**Notes to the Financial Statements - continued
for the Year Ended 31 March 2026**

13. RELATED PARTY DISCLOSURES

During the year company was charged consultancy fees amounting to £71,950 (2025: £86,250) by a company in which a director of TRUPCR Europe Limited is also a director. At the year end, the amount owed from the company was £6,420 (2025: £6,420).

14. ULTIMATE CONTROLLING PARTY

The ultimate controlling party of TRUPCR Europe Limited is 3B BlackBio Dx Limited, which is majority shareholder incorporated and registered in India. Copies of the consolidated financial statements of 3B BlackBio Dx Ltd can be obtained from registered address 7-C, Industrial Area, Govindpura, Bhopal 462023 [M.P.], India.

TRUPCR Europe Limited

**Trading and Profit and Loss Account
for the Year Ended 31 March 2026**

	2026		2025	
	£	£	£	£
Sales		1,750,863		1,287,580
Cost of sales				
Opening stock	54,473		43,606	
Purchases	1,046,101		762,350	
Commissions	8,680		34,898	
Carriage	86,344		69,855	
	1,195,598		910,709	
Closing stock	(47,039)		(54,473)	
		1,148,559		856,236
GROSS PROFIT		602,304		431,344
Other income				
Management charge	5,395		4,095	
Government grants	15,000		-	
Deposit account interest	-		1,215	
Other interest	29		47	
		20,424		5,357
		622,728		436,701
Expenditure				
Rent	33,791		53,004	
Rates and water	14,799		15,439	
Insurance	8,563		6,570	
Light and heat	3,894		2,248	
Wages	142,660		95,706	
Social security	7,162		4,972	
Pensions	3,027		2,188	
Telephone	2,115		288	
Post and stationery	2,560		2,987	
Advertising and promotions	43,259		42,759	
Travel and subsistence	2,956		2,996	
Repairs and renewals	9,068		1,424	
Cleaning	2,685		-	
Computer costs	5,699		3,712	
Sundry expenses	2,551		2,672	
Accountancy	2,500		2,500	
Subscriptions	11,264		8,302	
Consultancy fees	123,461		147,812	
Research and development	16,000		-	
Legal and professional fees	1,590		1,255	
Auditors' remuneration	5,000		5,000	
Donations	275		-	
Foreign exchange losses	7,249		8,566	
Carried forward	452,128	622,728	410,400	436,701

This page does not form part of the statutory financial statements

TRUPCR Europe Limited

**Trading and Profit and Loss Account
for the Year Ended 31 March 2026**

	2026		2025	
	£	£	£	£
Brought forward	452,128	622,728	410,400	436,701
Entertainment	1,133		-	
	<u> </u>	<u>453,261</u>	<u> </u>	<u>410,400</u>
		169,467		26,301
Finance costs				
Bank charges	1,302		825	
Bank loan interest	107		257	
Other interest	6,563		-	
	<u> </u>	<u>7,972</u>	<u> </u>	<u>1,082</u>
		161,495		25,219
Depreciation				
Development costs	2,796		2,796	
Improvements to property	2,529		12,408	
Plant and machinery	4,896		4,624	
Fixtures and fittings	683		648	
Computer equipment	1,347		683	
	<u> </u>	<u>12,251</u>	<u> </u>	<u>21,159</u>
NET PROFIT		<u><u>149,244</u></u>		<u><u>4,060</u></u>

This page does not form part of the statutory financial statements